1-3 of 3
Yajun Li
Close
Sort by
Journal Articles

Combining Selinexor with R-CHOP in the Treatment of Newly Diagnosed High-Risk (IPI 3-5) GCB Subtype DLBCL Patients: A Multicenter, Open Label Phase 2 Study

Zhiming Li, Hang Yang, Yanxue Yin, Yajun Li, Xue Gao, Peng Sun, Yu Wang, Lu Zhang, Hui Zhou, Keshu Zhou, Jay Mei
Journal: Blood
Blood (2023) 142 (Supplement 1): 6240.
https://doi.org/10.1182/blood-2023-181503
Published: 2023
Journal Articles

Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly-Diagnosed Advanced, Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: A Multicenter, Phase 2 Cohort of the Open-Label Spirit Study

Qingqing Cai, Panpan Liu, Yi Xia, Jun Cai, Huiqiang Huang, Zhiming Li, Hui Zhou, Yajun Li, Hanyu Wang, Ying Huang, Gao Yan, Xueyi Pan
Journal: Blood
Blood (2022) 140 (Supplement 1): 2299–2301.
https://doi.org/10.1182/blood-2022-168457
Published: 2022
Journal Articles

Safety and Preliminary Efficacy of Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen As First-Line Treatment for Patients with Advanced Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: An Open-Label, Multicenter, Phase 2 Study

Qingqing Cai, PhD, Huiqiang Huang, MDPhD, Panpan Liu, MD PhD, Hui Zhou, MD PhD, Yajun Li, MD PhD, Yujing Zhang, MD PhD, Lixia Lu, MD PhD, Yan Gao, MD PhD, Xuanye Zhang, MDPhD, Yi Xia, MD PhD, Jun Cai, BMBS, Ning Su, MM, Shuyun Ma, MM, Hang Yang, MD PhD, Yu Fang, BMBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-136949
Published: 2020